Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube May 11, 2026
Company Medical Device

Peijia Medical Receives NMPA Approval for DCwire Micro Guide Wire Device in China

Fineline Cube Jul 7, 2023

Peijia Medical Ltd (HKG: 9996), a leading Chinese firm in the neurointerventional field, has announced...

Company Deals

Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007

Fineline Cube Jul 7, 2023

Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement...

Company Deals

Sirnaomics Ltd Partners with Edirna Inc. to Advance RNA Editing Therapy

Fineline Cube Jul 6, 2023

Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced...

Policy / Regulatory

CDE Launches Trial Procedures for Adding Pediatric Information to Drug Inserts

Fineline Cube Jul 6, 2023

The Center for Drug Evaluation (CDE) has released the “Work Procedures for Adding Children’s Drug...

Company Deals

Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies

Fineline Cube Jul 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star...

Company Drug

3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus

Fineline Cube Jul 6, 2023

China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products...

Company Deals

Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements

Fineline Cube Jul 6, 2023

China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Esflurbiprofen Patch Clinical Study

Fineline Cube Jul 6, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development

Fineline Cube Jul 6, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with...

Company Deals

Nanjing Kati Medical and Leman Biotech Partner to Advance Immune Metabolism Reprogramming in CAR-T Therapy

Fineline Cube Jul 6, 2023

Nanjing Kati Medical Technology Co., Ltd, a China-based company, has entered into a partnership with...

Company Deals

Brii Biosciences Expands Collaboration with VBI Vaccines on Hepatitis B Virus Therapies

Fineline Cube Jul 6, 2023

China-based Brii Biosciences Ltd (HKG: 2137) has announced an expanded license agreement with US firm...

Policy / Regulatory

NMPA Launches “Drug Standard Management Measures” to Enhance Drug Quality and Safety

Fineline Cube Jul 6, 2023

The National Medical Products Administration (NMPA) has released the “Drug Standard Management Measures,” a set...

Company Policy / Regulatory

China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities

Fineline Cube Jul 6, 2023

This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a...

Company Legal / IP

Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy

Fineline Cube Jul 6, 2023

Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award...

Company

Moderna Inc. Plans USD 1 Billion Investment in Shanghai for mRNA Vaccine Production

Fineline Cube Jul 6, 2023

US-based mRNA specialist Moderna Inc. (NASDAQ: MRNA) has revealed further details of its entry into...

Company Drug

CSPC Pharmaceutical Group Receives Marketing Approval for Desvenlafaxine in China

Fineline Cube Jul 6, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving marketing approval in China for...

Company Drug

AbbVie’s Rinvoq Receives NMPA Approval for Moderate to Severe Crohn’s Disease Treatment

Fineline Cube Jul 6, 2023

US pharmaceutical firm AbbVie (NYSE: ABBV) has announced receiving market approval from the National Medical...

Company Drug

Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment

Fineline Cube Jul 5, 2023

Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...

Policy / Regulatory

CDE Releases 72nd Batch of Generic Reference Preparations with New Specifications

Fineline Cube Jul 5, 2023

The Center for Drug Evaluation (CDE) has released the 72nd batch of chemical generic reference...

Company Drug

Huadong Medicine’s Liraglutide Biosimilar Gains NMPA Approval for Weight Loss Indication

Fineline Cube Jul 5, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received additional indication...

Posts pagination

1 … 503 504 505 … 663

Recent updates

  • GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market
  • Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms
  • Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor
  • Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
  • MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.